TopFunds

Quest Diagnostics

NYSE: DGX

Stock price

230.81 USD

(+0%) TODAY

Health Care ServicesMedical - Diagnostics & Research
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
4.9
4.5
5.5
5.3
6.3
10.5
15.5
8
7.5
7.7
8.8
6%
02Free cash flow per share
3.8
5.5
6.6
5.9
6.2
11.7
14.3
11.1
7.6
8
12
12.3%
03Dividends per share
1.5
1.6
1.8
2
2.1
2.2
2.4
3.3
2.8
3
3.2
7.9%
04Dividends payout, %
29.9%
34.6%
32%
36.1%
33.3%
20.8%
15.5%
32.2%
36.8%
38%
35.6%
1.8%
PROFIT AND LOSS STATEMENT
05Revenue
7,493
7,515
7,709
7,531
7,726
9,437
10,788
9,883
9,252
9,872
11,035
4%
06% Change
-
-
-
-
-
-
-
-
-
-
-
4%
07Cost of revenue
(4,657)
(4,616)
(4,719)
(4,926)
(5,037)
(5,804)
(6,579)
(6,450)
(6,199)
(6,628)
(7,512)
4.9%
08Gross profit
2,836
2,899
2,990
2,605
2,689
3,633
4,209
3,433
3,069
3,244
3,523
2.2%
09% Margin
37.9%
38.6%
38.8%
34.6%
34.8%
38.5%
39%
34.7%
33.2%
32.9%
31.9%
35.9% A
10Operating expenses
(1,771)
(1,740)
(1,825)
(1,500)
(1,458)
(1,662)
(1,828)
(2,005)
(1,807)
(1,898)
(1,920)
0.8%
11% of Revenue
(23.6)%
(23.2)%
(23.7)%
(19.9)%
(18.9)%
(17.6)%
(16.9)%
(20.3)%
(19.5)%
(19.2)%
(17.4)%
(20)% A
12Operating Income
1,399
1,277
1,165
1,101
1,231
1,971
2,381
1,428
1,262
1,346
1,603
1.4%
13Income tax expense
(373)
(429)
(241)
(182)
(247)
(460)
(597)
(264)
(248)
(273)
(314)
(1.7)%
14Net Income
709
645
772
736
858
1,431
1,995
946
854
871
992
3.4%
15% Margin
9.5%
8.6%
10%
9.8%
11.1%
15.2%
18.5%
9.6%
9.2%
8.8%
9%
10.8% A
16Shares Outstanding
145
142
140
139
136
136
128
118
113
113
113
(2.5)%
17EPS Basic
4.9
4.6
5.6
5.4
6.4
10.7
15.9
8.1
7.6
7.8
8.9
6.1%
18EPS Diluted
4.9
4.5
5.5
5.3
6.3
10.5
15.5
8
7.5
7.7
8.8
6%
19EBITDA
1,555
1,479
1,453
1,404
1,585
2,411
3,159
1,820
1,732
1,894
2,194
3.5%
% Margin
20.8%
19.7%
18.9%
18.6%
20.5%
25.6%
29.3%
18.4%
18.7%
19.2%
19.9%
20.9% A
20Net Interest Income (expense)
(153)
(143)
(151)
(167)
(175)
(163)
(151)
(138)
(152)
(201)
(264)
5.6%
21Net Debt / EBITDA
2.3
2.3
2.6
2.7
2.7
1.5
1.2
2.4
2.8
3.5
3
2.4 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
133
359
137
135
1,192
1,158
872
315
686
549
420
12.2%
23Short-term investments
-
-
-
-
-
-
-
-
-
-
-
-
24Accounts receivable
901
926
924
1,012
1,063
1,520
1,438
1,195
1,210
1,304
1,408
4.6%
25Other current assets
217
164
150
144
112
157
223
196
286
351
361
5.2%
26Inventory
84
82
95
99
123
223
208
192
190
188
189
8.5%
27Total Current Assets
1,501
1,531
1,306
1,390
2,490
3,058
2,741
1,898
2,372
2,392
2,378
4.7%
Non-Current Assets
28Net property, plant & equipment
925
1,029
1,145
1,288
1,971
2,231
2,304
2,351
2,418
2,764
2,860
12%
29Long-term investments
473
443
462
436
482
521
141
132
135
123
136
(11.7)%
30Other non-current assets
7,063
7,097
7,590
7,889
7,900
8,216
8,425
8,456
9,097
10,874
10,851
4.4%
31Total Non-Current Assets
8,461
8,569
9,197
9,613
10,353
10,968
10,870
10,939
11,650
13,761
13,847
5.1%
Total Assets
9,962
10,100
10,503
11,003
12,843
14,026
13,611
12,837
14,022
16,153
16,225
5%
LIABILITIES
Current Liabilities
32Accounts payable
279
261
224
222
263
446
357
324
378
287
1,600
19.1%
33Short-term debt
159
6
107
562
1,037
296
269
247
585
937
678
15.6%
34Other current liabilities
735
714
726
701
690
1,034
1,127
980
852
945
-
2.8%
35Total Current Liabilities
1,173
981
1,057
1,485
1,990
1,776
1,753
1,551
1,815
2,169
2,278
6.9%
Non-Current Liabilities
36Long-term debt
3,492
3,728
3,748
3,429
4,379
4,512
4,504
4,467
4,913
6,150
6,241
6%
37Other non-current liabilities
514
654
663
745
711
847
792
812
876
938
420
(2)%
38Total Non-Current Liabilities
4,006
4,382
4,411
4,174
5,090
5,359
5,296
5,279
5,789
7,088
6,661
5.2%
39Total Liabilities
5,179
5,363
5,468
5,659
7,080
7,135
7,049
6,830
7,604
9,257
8,939
5.6%
SHAREHOLDERS` EQUITY
40Common stock
2
2
2
2
2
2
2
2
2
2
2
-
41Retained earnings / (deficit)
6,199
6,613
7,138
7,602
8,174
9,303
7,649
8,290
8,825
9,360
9,994
4.9%
42Accumulated other comprehensive income / (loss)
(38)
(72)
(48)
(59)
(39)
(21)
(14)
(21)
(14)
(88)
(27)
(3.4)%
43Noncontrolling interests
99
109
114
128
122
132
118
114
111
118
116
1.6%
44Total shareholders' equity
4,783
4,737
5,035
5,344
5,763
6,891
6,562
6,007
6,418
6,896
7,286
4.3%
45Total Liabilities and shareholders' Equity
9,962
10,100
10,503
11,003
12,843
14,026
13,611
12,837
14,022
16,153
16,225
5%
46Total Debt
3,651
3,734
3,855
3,991
5,416
4,808
4,773
4,714
5,498
7,087
6,919
6.6%
47Net Debt
3,518
3,375
3,718
3,856
4,224
3,650
3,901
4,399
4,812
6,538
6,499
6.3%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
709
645
772
736
858
1,431
1,995
946
854
871
992
3.4%
49Depreciation & amortization
304
249
270
309
329
361
408
437
439
493
570
6.5%
50Share-based compensation expense
52
69
79
61
56
97
79
77
77
88
88
5.4%
51Changes in working capital and other assets
(255)
106
54
94
-
116
(249)
258
(98)
(118)
236
-
52Net cash flows from operating activities
810
1,069
1,175
1,200
1,243
2,005
2,233
1,718
1,272
1,334
1,886
8.8%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(263)
(293)
(252)
(383)
(400)
(418)
(403)
(404)
(408)
(425)
(527)
7.2%
54Purchases of investments / marketable securities
263
293
252
383
(44)
(27)
(3)
(5)
-
-
-
-
55Proceeds from maturities of marketable securities
1
10
2
1
400
418
403
5
-
-
-
25.9%
56Other investing activities
(363)
(162)
(807)
(802)
(367)
(745)
24
(139)
(653)
(2,123)
(104)
(11.8)%
57Net cash flows from investing activities
(362)
(152)
(805)
(801)
(411)
(772)
21
(543)
(1,061)
(2,548)
(631)
5.7%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(224)
(590)
(465)
(322)
(353)
(325)
(2,199)
(1,408)
(275)
(151)
(371)
5.2%
59Dividends paid, net
(212)
(223)
(247)
(266)
(286)
(297)
(309)
(305)
(314)
(331)
(353)
5.2%
60Debt issuance (repayments), net
(84)
141
23
124
832
(805)
(2)
(2)
748
1,543
(602)
21.8%
61Other financing activities
13
(19)
97
63
32
160
(30)
(17)
1
23
(62)
-
62Net cash flows from financing activities
(507)
(691)
(592)
(401)
225
(1,267)
(2,540)
(1,732)
160
1,084
(1,388)
10.6%
63Increase (decrease) in cash and cash equivalents
(59)
226
(222)
(2)
1,057
(34)
(286)
(557)
371
(137)
(129)
8.1%
64Cash and equivalents, ending balance
133
359
137
135
1,192
1,158
872
315
686
549
420
12.2%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
547
776
923
817
843
1,587
1,830
1,314
864
909
1,359
9.5%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Quest Diagnostics (DGX) financial statements and performance

Explore Quest Diagnostics (DGX) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.